The
investigators also observed problems with NECC’s ability to maintain
its clean room, which is the enclosed space that is designed and
maintained to have a controlled environment with low levels of airborne
particles and surface contamination. Production of sterile drug products
in a properly functioning and maintained clean room reduces the risk of
the introduction of microbial contamination into the
drug during processing, including filling into its final container..."
Tuesday, October 30, 2012
FDA reports conditions observed at New England Compounding Center
"Today, the U.S. Food and Drug Administration
released a copy of the FDA Form 483 issued to the New England
Compounding Center (NECC). The FDA observed and has since confirmed
contaminated products and listed a number of observations regarding
conditions in the clean room at NECC’s Framingham, Mass. facility.
FDA Report on New England Compounding
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment